1-3 of 3
Anastasia Banti, MD
Close
Sort by
Journal Articles

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Dimitra Mihou, MD, Vassiliki Gastari, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2738.
https://doi.org/10.1182/blood.V110.11.2738.2738
Published: 2007
Journal Articles

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4813.
https://doi.org/10.1182/blood.V110.11.4813.4813
Published: 2007
Journal Articles

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4814.
https://doi.org/10.1182/blood.V110.11.4814.4814
Published: 2007